The beneficial effects of statins are usually assumed to stem from their ability to reduce cholesterol biosynthesis. However, because statins are potent inhibitors of the mevalonate, which governs diverse cell signaling pathways, inhibition of 3-hydroxy-3-methylglutaryl-coenzyme-A reductase may also result in pleiotropic effects. The present study describes a novel pleiotropic effect of statins on vascular endothelial growth factor (VEGF)-induced glomerular endothelial cell (GEnC) hyperpermeability. Using live cell imaging with green fluorescent protein-tagged myosin regulatory light chain (MLC) and correlative biochemical analyses, we investigated 1) VEGF signaling pathway leading to GEnC hyperpermeability and 2) the modulatory effects of statins on VEGF signaling. Our findings indicate that VEGF stimulation elicits a robust increase in GEnC permeability. The signaling pathway that mediates VEGF-induced GEnC hyperpermeability involves RhoA activation leading to actin cytoskeletal remodeling, MLC diphosphorylation, and enhanced paracellular gap formation. Remarkably, cotreatment of endothelial cells with simvastatin, a hydrophobic statin, reversed VEGF-induced GEnC hyperpermeability by preventing MLC diphosphorylation, and cytoskeletal remodeling. In summary, this study identifies RhoA and MLC phosphorylation as key mediators of VEGFinduced endothelial cell hyperpermeability and demonstrates the modulatory effects of statins on VEGF signaling pathway.
ur understanding of the complex pathobiology of the vascular endothelial growth factor (VEGF) in health and disease has recently been greatly enhanced. For instance, the involvement of VEGF in the pathogenesis of diabetic nephropathy (DN), a common microvascular complication of both type 1 and type 2 diabetes, has been recently supported by in vitro as well as in animal models of diabetes in vivo (1) (2) (3) . Using a neutralizing anti-VEGF antibody, two recent studies have shown a significant decrease in hyperfiltration and albuminuria, hallmarks of DN, in two established animal models of diabetes (2, 3) . However, despite several lines of evidence suggesting a central role for VEGF in the pathogenesis of microvascular complications of diabetes, the underlying cellular and molecular mechanisms of detrimental effects of VEGF remain largely unknown.
VEGF, also known as vascular permeability factor, is a multifunctional cytokine that plays key roles in diverse biological activities of endothelial cells (4) (5) (6) . In the kidneys, it is known that VEGF is constitutively expressed, with its glomerular expression being mainly confined to glomerular podocytes (6, 7) . The expression of VEGF in the podocytes is seemingly paradoxical to the expression of its specific receptors on the glomerular endothelial cells (GEnC). However, the peculiar anatomy of microvasculature in the glomerular capillaries may suggest the possibility of crosstalk, probably via heparan sulfate proteoglycans (i.e., glypican-1), which may act as a shuttle to transport VEGF across the basement membrane to GEnC (7, 8) .
A major gap in our understanding of the pathogenic role of VEGF in DN is the underlying molecular mechanism(s) through which VEGF exerts its deleterious effects on glomerular microvasculature. To address this question and to obtain insight into the actual molecular effect of VEGF on endothelial barrier integrity, we have investigated signaling pathways elicited by VEGF that result in GEnC hyperpermeability.
Because of accumulating evidence indicating that members of the Ras-homology (Rho) family of small GTPases, Rho, Rac, and Cdc42 are important regulators of endothelial permeability, we postulated that VEGF-induced GEnC hyperpermeability is mediated by RhoA activation. The Rho family of small GTP binding proteins cycle between a GDP-bound (inactive) state and a GTP-bound (active) state (9, 10) . Activation of Rho GTPases is accompanied by their intracellular translocation and recruitment from the cytoplasm to the plasma membrane (9, 10) . Increasing evidence has demonstrated that RhoA activation promotes stress fiber formation and activation of actomyosin interaction by up-regulating phosphorylation of myosin regulatory light chain (MLC) (11, 12) . Indeed, previous studies have reported that phosphate incorporation at Ser19 and Thr18 of the MLC not only increases actomyosin ATPase activity, but also destabilizes the endothelial cell−cell junctions leading to increased monolayer cell permeability (13, 14) .
The 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) reductase inhibitors, or statins, are potent inhibitors of cholesterol synthesis that are extensively used in the treatment of patients with hypercholesterolemia (15) (16) (17) . Remarkably, statins have also been postulated to confer renoprotection in a variety of glomerular diseases, including DN (17) (18) (19) . It is usually assumed that the beneficial effects of statins result from the competitive inhibition of cholesterol biosynthesis. However, we have recently proposed that statins may also modulate several key signaling pathways, beyond their cholesterol-lowering properties, in the diabetic milieu by preventing the activation of Rho family of small GTPases (20) (21) (22) In the present study, we investigated the molecular mechanisms of VEGF-mediated GEnC hyperpermeability, and explored the modulatory effects of statins on VEGF-induced Rhomediated signaling pathway involving MLC phosphorylation and actin cytoskeleton remodeling.
MATERIALS AND METHODS

Materials
Recombinant rat VEGF-A 164 was obtained from R&D Systems (Minneapolis, MN). Anti-RhoA and anti-diphospho MLC (Ser19/Thr18) antibodies were purchased from Santa Cruz Biotechnology (Santa Cruz, CA). Rhodamine-labeled phalloidin was purchased from Molecular Probes (Eugene, OR). Y27632 was obtained from Calbiochem (San Diego, CA). ECL and glutathione-sepharose 4B beads were obtained from Amersham Biosciences (Piscataway, NJ). Simvastatin was kindly provided by Merck and Co. (West Point, PA). Simvastatin and mevalonate (Sigma, St. Louis, MO) were activated by alkaline hydrolysis as described previously (37, 38) .
Cell culture and transfection
Rat GEnC were established and characterized as described previously (23) . Briefly, GEnC (4th to 10th passage) were grown in RPMI1640 medium supplemented with 10% fetal bovine serum (FBS), 10% NuSerum, 100 U/ml penicillin, and 100 µg/ml streptomycin in a humidified incubator at 37°C under 5% CO 2 . In experiments using simvastatin, cells were preincubated with simvastatin for 24 h before VEGF exposure. To generate MLC-green fluorescence protein (GFP) expression plasmid, myosin II MLC was PCR-amplified to introduce KpnI and BamHI sites for subcloning into pEGFP-C1 (Clontech, Palo Alto, CA). The cDNA insert was sequenced in its entirety to ensure that the construct is mutation-free. Large-scale plasmid preparation was performed using Endo-Free plasmid purification kit (Qiagen, Valencia, CA) to eliminate the presence of endotoxin, which can compromise transfection efficiency. Transfection studies for GFP-tagged MLC were performed by electroporation. Briefly, cells were trypsinized and pelleted by centrifugation and resuspended in 1 ml of appropriate medium. Two hundred microliters of the resuspended cells were mixed with 7 μg DNA containing 13 μg sheared salmon sperm DNA and electroporated in 4-mm cuvettes using Bio-Rad (Hercules, CA) Gene Pulser set at 200 Ω, 960 μFD, 250 V. Using this method, we achieved a transfection efficiency of ∼10%. Other transfection studies were carried out using Lipofectamine (Invitrogen, Carlsbad, CA) as by manufacturer's instructions. Briefly, cells were plated on six-well plates before transfection. At 40-50% of confluency, cells were transfected with 2 µg of the corresponding DNA. After 72 h, cells were placed in the selective medium containing 800 µg/ml of genectin. After 3 wk, colonies were picked and expanded for the experiments. The plasmids encoding the dominant-negative RhoA mutant (pcDNA3 AN19Rho) and wild-type RhoA (pcDNA3 wtRhoA) were kind gifts of Dr. Jacob Sznajder (Northwestern University).
RhoA activation assay
This method is a pulldown affinity assay based on the ability of the Rho binding domain (RBD) of Rhotekin to selectively bind the GTP-loaded form of Rho. Briefly, DH5α E. coli culture transformed with pGEX-2T plasmid encoding the recombinant glutathione-S-transferase (GST)-RBD protein was pelleted and dissolved in 10 ml STE buffer (10 mM Tris [pH 8.0], 150 mM NaCl, and 1 mM EDTA). The supernatant was incubated with 1 ml glutathione-sepharose 4B beads for 1 h at 4°C by constant agitation. Cells were then washed with ice-cold phosphatebuffered saline (PBS), lysed, and scraped in 500 µl of lysis buffer. The detergent-insoluble fraction was removed by centrifugation, and the supernatants were incubated with 20 µg of GST-RBD for 45 min. The GST-RBD-covered beads were boiled in 25 µl of 2× Laemmli buffer for 5 min. The bead-associated proteins were resolved by 15% SDS-PAGE, and the captured Rho protein was detected by Western blotting using a monoclonal anti-Rho A antibody.
Transendothelial electrical resistance
The electrical resistance of the confluent GEnC monolayer was measured using MillicellElectrical Resistance System (Millipore, Bedford, MA). GEnC were grown until postconfluency on Transwell filters (Corning, Corning, NY). For measurements, both apical and basolateral sides of the endothelial cells were bathed with Hank's balanced salt solution. Electrical resistance was recorded from probes inserted into the buffer inside and outside the inserts until similar values were reproducible on three consecutive measurements. The measured potential difference between the upper and the lower wells was used to calculate the electrical resistance (Ω/cm 2 ). Transendothelial electrical resistance (TEER) values were then calculated by subtracting the inherent resistance of the filter and the bathing solution.
Confocal laser scanning fluorescence microscopy
GEnC were cultured on 25-mm coverslips. After the coverslips were washed with PBS, cells were fixed in 2% formaldehyde/PBS for 5 min and permeabilized in 0.1% Triton X-100. For Factin staining, the coverslips were incubated with rhodamine-labeled phalloidin for 30 min. After washing with PBS, the coverslips were mounted on glass slides with Gelavatol mounting medium. Samples were viewed using Zeiss LSM510 laser scanning confocal microscopy .
Live cell imaging
Live GEnC transfected with GFP-tagged MLC were imaged in a Bioptechs FCS2 closed chamber system maintained at 37°C, with a chamber thickness of 0.75 mm. The perfusion chamber is fitted onto a Nikon TE2000U inverted microscope, equipped with a Yokogawa spinning disc confocal system. The system is illuminated with Coherent Innova-70 and Omnichrome-500 lasers (Prairie Technologies, Middleton, WI). Digital fluorescent images were captured by Micromax cooled CCD camera (Roper Scientific, Tucson, AZ) with a 512 × 512 camera chip. Cell images were taken using MetaMorph 6.1 (Universal Imaging Corp., Downingtown, PA) software. The images were taken with 200 ms exposures.
Western blotting
Cell membrane fractions were purified as described previously (20, 21) . Briefly, cells were resuspended in 10 mM Tris·HCl (pH 7.4)/10 mM NaCl/1.5 mM MgCl 2 /0.02 mM PMSF, and homogenized in a Dounce homogenizer. The homogenate was centrifuged at 1000 g for 10 min. The supernatant was overlaid on 35% sucrose solution and centrifuged for 60 min at 18,000 g. The membrane fraction at the interface was removed and resuspended in 10 mM Tris·HCl (pH 7.4)/250 mM sucrose (buffer A). The sample then was centrifuged, and the pellets were resuspended in the buffer A and stored at 4°C. Equal amounts of protein were subjected to SDS/PAGE analysis and then electroblotted onto nylon membranes. The membranes were incubated with primary antibodies at 4°C overnight, washed extensively, and incubated with the appropriate peroxidase-conjugated secondary antibodies. After the final washes, immunoreactive bands were visualized by ECL enhanced chemiluminescence reaction.
Statistical analysis
Data are presented as mean ± SE for the number of experiments (n) indicated. ANOVA with a Student-Neuman-Keul's test was used to evaluate differences between the means of data obtained from two or more different experimental groups. P ≤ 0.05 was considered as statistically significant.
RESULTS
Effect of simvastatin on VEGF-induced permeability
To assess the role of simvastatin on VEGF-induced hyperpermeability, we measured TEER across GEnC. GEnC were grown until postconfluent on Transwell filters and exposed to various concentrations of VEGF (25, 50, and 100 ng/ml), and the electrical resistance of the filter was subsequently measured using a Millicell-Electrical Resistance System. After 30 min of exposure to various concentrations of VEGF, GEnC displayed a significant decrease in TEER in a dosedependent manner (Fig. 1A) . To determine the effect of simvastatin on VEGF-induced GEnC hyperpermeability, we measured TEER in untreated, VEGF-stimulated (50 ng/ml) GEnC and in cells cotreated with simvastatin (1 μM) and mevalonate (400 μM). VEGF exposure lowered basal TEER levels by ∼60% (Fig. 1B) . Simvastatin alone did not significantly affect the permeability of GEnC. Similarly, TEER levels did not change significantly when VEGFstimulated cells were cotreated with simvastatin, indicating that simvastatin attenuates VEGFinduced GEnC hyperpermeability. Addition of mevalonate to cells cotreated with VEGF and simvastatin decreased TEER to the levels obtained with VEGF, suggesting that the inhibitory effect of simvastatin on VEGF-induced GEnC hyperpermeability is via a mevalonate-dependent pathway.
Effects of VEGF and simvastatin on RhoA activation
We had previously shown that statins (e.g., simvastatin) may exert their beneficial effects in the diabetic milieu by inhibiting geranylgeranylation of the Rho family of small GTPases (20) (21) (22) . To evaluate the role of RhoA in VEGF-induced signaling pathway, a pulldown assay using the fusion protein GST-RBD, which recognizes only RhoA-GTP (the active form of RhoA), was performed. As shown in Fig. 2A , RhoA-GTP was significantly increased when cells were exposed to various concentrations of VEGF for 5 min. To elucidate the modulatory effect of simvastatin on VEGF-induced GEnC hyperpermeability, cells were exposed to VEGF (50 ng/ml) and cotreated with simvastatin (1 μM). Treatment of GEnC with VEGF for 5 min increased RhoA-GTP by about fivefold (Fig. 2B) . Simvastatin alone did not have any significant effect on RhoA activity. However, cotreatment of VEGF-stimulated cells with simvastatin significantly decreased RhoA activity.
To further support the involvement of RhoA on VEGF signaling pathway, we also compared membrane-bound RhoA (active form) to the total cytoplasmic protein expression of RhoA using Western blot analysis. As shown in Fig. 3A , increased protein expression of membrane-bound RhoA in GEnC was observed after 5 min of stimulation with various concentrations of VEGF with reciprocal changes in cytoplasmic RhoA protein levels. Furthermore, cotreatment of cells with simvastatin (1 μM) reversed VEGF-induced (50 ng/ml) increase in membrane-associated RhoA, suggesting that the simvastatin prevents VEGF-induced translocation of RhoA to the membrane (Fig. 3B) .
RhoA activation and VEGF-induced GEnC hyperpermeability
We then investigated whether RhoA activation contributes to the observed VEGF-induced GEnC hyperpermeability. To answer this question, GEnC were transfected with wild-type RhoA (wtRhoA), and dominant-negative mutant of RhoA (N19RhoA). Using the monolayer resistance assay, cells transfected with wtRhoA and exposed to VEGF (50 ng/ml) showed a significant decrease in the measured TEER (Fig. 4) . Unstimulated N19RhoA transfected cells did not affect the measured resistance. Interestingly, transfected GEnC with N19RhoA and stimulated with VEGF (50 ng/ml) failed to display a significant change in the measured TEER. These findings support the role of RhoA as a key mediator of the VEGF-induced hyperpermeability in GEnC.
Effects of VEGF and simvastatin on cytoskeletal remodeling
Our observation that VEGF rapidly induced the activation of RhoA, and that simvastatin ameliorated the effect of VEGF, suggests that VEGF and statins may affect GEnC permeability via cytoskeleton remodeling. To establish whether the VEGF-induced hyperpermeability involves cytoskeletal remodeling, we characterized F-actin cytoskeletal network in GEnC by rhodamine-conjugated phalloidin staining. GEnC do not generally display prominent stress fibers, although they exhibit an extensive cortical actin network (Fig. 5A) . Within 20 min of VEGF treatment (25, 50, and 100 ng/ml), cells exhibited significant stress fiber formation, and sizable gaps (arrows) between endothelial cells appeared in a dose-dependent manner (Fig. 5B-D) . However, VEGF stimulation (50 ng/ml) failed to induce stress fiber formation and paracellular gap formation in dominant-negative RhoA-transfected GEnC as well as in cells cotreated with simvastatin (1 μM) (Fig. 5E, 5F ). These observations suggest that VEGF signaling pathway involves cytoskeletal reorganization. Moreover, our data indicate that simvastatin ameliorates VEGF-induced cytoskeletal remodeling.
Effects of VEGF and simvastatin on MLC diphosphorylation
One of the best characterized triggering signals for stress fiber formation is phosphorylation of the regulatory part of the myosin molecule. MLC phosphorylation plays a pivotal role in initiating actin-myosin interaction and the development of F-actin-dependent cytoskeletal contractile tension (13, 14) . Previous reports have indicated that Rho/Rho kinase pathway may contribute to MLC phosphorylation in smooth muscle cells as well as in endothelial cells (12) (13) (14) . To assess whether VEGF-induced cytoskeletal remodeling involves MLC diphosphorylation, we induced GEnC with VEGF (50 ng/ml), and assessed MLC diphosphorylated state by Western blot analysis using anti-diphosphorylated MLC antibody (Santa Cruz Biotechnology). As shown in Fig. 6A and 6B, VEGF exposure significantly
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increased protein levels of diphosphorylated MLC. Cotreatment of cells with simvastatin (1 μM) inhibited VEGF-induced MLC diphosphorylation. Addition of mevalonate (400 μM) resulted in a significant increase in diphosphorylated MLC, indicating that the effect of simvastatin on MLC diphosphorylation was mevalonate-dependent.
To gain further insight as to whether Rho/Rho kinase pathway mediates VEGF-induced MLC diphosphorylation, GEnC transfected with wtRhoA and dominant-negative RhoA (N19RhoA) and cells cotreated with Y27632 (10 μM), a Rho-kinase inhibitor, were exposed to VEGF (50 ng/ml). As shown in Fig. 6C , VEGF exposure in wild-type RhoA-transfected cells significantly increased MLC diphosphorylation. However, N19RhoA-transfected cells as well as GEnC cotreated with Y27632 exhibited no significant change in diphosphorylated MLC, indicating that VEGF-induced MLC diphosphorylation in GEnC is RhoA-dependent.
Effects of VEGF and simvastatin on GEnC contraction
Myosin-dependent cell contraction plays a key role in endothelial cell permeability in response to inflammatory cytokines such as histamine and thrombin (24) (25) (26) (27) . To approach the central question of whether VEGF-induced GEnC hyperpermeability is directly mediated through cellular contraction, GEnC contraction was assessed by live cell imaging. GEnC transiently expressing GFP-tagged MLC were treated with VEGF (50 ng/ml) in a Bioptechs FCS2 perfusion chamber. Images were captured at indicated intervals on a spinning disc confocal microscope. As shown in Fig. 7A and 7B as well as in supplemental videos (videos 1 and 2), VEGF exposure (50 ng/ml) dynamically induced GEnC contraction leading to increased gaps among endothelial cells. However, cotreatment of cells with simvastatin (1 μM) significantly attenuated VEGFmediated cellular contraction and paracellular gap formation (Fig. 7C and video 2) .
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DISCUSSION
The data presented in this study demonstrated that 1) simvastatin ameliorated VEGF-induced GEnC hyperpermeability, 2) VEGF-induced activation and recruitment of RhoA from the cytosol to the membrane led to MLC diphosphorylation and cytoskeletal remodeling, and 3) simvastatin, by inhibiting RhoA activation, prevented VEGF-induced MLC diphosphorylation and stress fiber formation. Based on our findings, we propose that the underlying molecular mechanism of VEGF-induced GEnC hyperpermeability involves RhoA activation, MLC diphosphorylation, endothelial cytoskeletal remodeling, and increased cellular contraction. Endothelial cell contraction results in increased paracellular gap formation and GEnC hyperpermeability.
The precise role of VEGF in the kidneys and the molecular mechanism of VEGF-induced hyperpermeability in GEnC are largely unknown. This is in part because most investigators have primarily focused on the angiogenic and mitogenic properties of VEGF. Thus, until recently, little was known regarding the cellular signaling pathways involved in the VEGF-mediated hyperpermeability. Previous in vitro studies aimed at identifying VEGF-mediated signaling pathways have suggested that VEGF-induced endothelial cell hyperpermeability involves the sequential phosphorylation of Src, ERK, JNK, and PI 3-kinase/Akt pathway, leading to ZO-1 and occludin redistribution (28). Chen et al. have proposed that VEGF may also increase vascular permeability by increasing the density of clustered caveolae in endothelial cells (29) . Similarly, Vasile et al. have demonstrated the importance of VEGF-induced caveolar clustering in bovine microvascular endothelial cells (30) . However, the findings of these studies have been recently challenged, and it seems that VEGF-induced endothelial permeability, at least in vivo, is not caveolae-dependent (31) . Remarkably, the effect of VEGF on one of the most important molecular mechanisms involved in endothelial cell permeability, namely MLC phosphorylation and active cytoskeletal remodeling, was not previously explored until the present study.
In the current study, we demonstrated that VEGF-mediated hyperpermeability in GEnC is mediated by RhoA activation that results in MLC diphosphorylation, stress fiber formation, and cytoskeletal remodeling. In addition, live cell imaging provided further insight into the "realtime" effect of VEGF on GEnC permeability by demonstrating that exposure of GEnC to VEGF leads to increased cellular contraction and enhanced paracellular gap formation. Taken together, our findings elucidate for the first time the pivotal role of MLC phosphorylation and cell contraction as the underlying molecular mechanism of VEGF-induced GEnC permeability.
Our data point to an important role for RhoA in the regulation of endothelial permeability. The integration of these data with pathobiology of microvascular complications of diabetes is of paramount importance. Indeed, we had previously reported the critical role of several members of Rho family of small GTPases in two other important signaling cascades in the diabetic milieu, that is, angiotensin II and glucose-mediated signaling pathways (20) (21) (22) . We now report that Rho GTPases via cytoskeletal remodeling and MLC diphosphorylation are key regulators of VEGFinduced endothelial dysfunction. Furthermore, we extended our previous observations by establishing that RhoA is essential for VEGF-induced MLC diphosphorylation since GEnC transfected with dominant-negative RhoA failed to exhibit MLC diphosphorylation and increased endothelial permeability. Although RhoA was the target of our study, other members of Rho family of small GTPases (e.g., Rac1) may also be implicated in regulating VEGFinduced GEnC hyperpermeability. For instance, Rac1 has been recently shown to regulate thrombin-induced endothelial cell permeability (32, 33) . Ongoing studies in our laboratory are exploring the individual roles of RhoA and Rac1 on VEGF-induced signaling pathway and the potential use of Rho GTPases as drug discovery targets in microvascular complications of diabetes.
A highly provocative finding of this study is the modulatory role of statins on VEGF-induced signaling pathway. Recent experimental evidence on the pleiotropic effects of statins suggests that statins may exert various modulatory effects on vascular endothelium by preventing isoprenylation of small GTPase proteins (34) (35) (36) . In support of a modulatory effect of statins in the diabetic milieu, we and others have recently proposed that the possible beneficial effects of statins in the diabetic milieu may be independent of their cholesterol-lowering properties and mediated, at least in part, by the modulatory effects of statins on Rho-dependent pathways (20) (21) (22) . The present study provides a novel observation on the pleiotropic effects of statins with (37, 38) . However, the molecular mechanism of the beneficial effects of statins in DN remains to be elucidated. In the current study, we identified a novel pleiotropic effect of simvastatin, a hydrophobic statin, on GEnC permeability. Our data indicate that simvastatin, by preventing RhoA activation, inhibits MLC phosphorylation, stress fiber formation, and cytoskeletal remodeling. Live cell imaging studies further demonstrated that the inhibitory effect of simvastatin on MLC-induced cell contraction and paracellular gap formation. These results provide evidence for a novel modulatory effect of simvastatin on endothelial cell permeability by preventing MLC phosphorylation and suggest a potential renoprotective of statins in microvascular complications of diabetes.
In conclusion, our findings have identified RhoA GTPase activation, cytoskeletal remodeling, and MLC phosphorylation as key mediators of VEGF-induced GEnC hyperpermeability. Furthermore, we demonstrated that simvastatin, by inhibiting RhoA activation, modulates VEGF-induced RhoA-mediated downstream signaling pathway. Although some assumptions of our proposal remain to be tested in vivo, our data provide a framework to establish the role of Rho GTPases in microvascular complications of diabetes and offer a new rationale for the use of statins in the early stages of DN, independent of their cholesterol-lowering properties.
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